NEW YORK and DALLAS, Oct. 27,
2021 /PRNewswire/ -- Code Ocean, the leading
computational research environment for sharing scientific
discoveries, today announced a collaboration that will power
AI-driven computational research for oncology-focused drug
discovery with Lantern Pharma (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary
RADR® artificial intelligence ("A.I.") platform to transform
the cost, pace, and timeline of oncology drug discovery and
development. By leveraging Code Ocean's Compute
Capsule® technology, the move will further power Lantern
Pharma's RADR® platform for faster,
more collaborative discoveries from billions of
RADR® data points as well as from experimental
results and insights from their network of collaborators.
![Faster, More Collaborative, Higher Quality Discoveries Faster, More Collaborative, Higher Quality Discoveries](https://mma.prnewswire.com/media/1669382/Code_Ocean_Logo.jpg)
Computational researchers today are challenged with analyzing
big data with too many tools, lack of specialized coding
experience, and challenging, cumbersome DevOps processes required
to organize and securely share research. Through this collaboration
Lantern Pharma is expected to benefit from significant efficiencies
in development time and cost as well as increased reproducibility
from Code Ocean's platform. The Code Ocean platform
will offer an easy to use, collaborative research experience with
an integrated development environment, secure repository, and
portable Compute Capsule® technology for guaranteed
reproducibility.
"I'm thrilled to be working with a
leading-edge partner like Lantern Pharma," said Simon Adar,
Co-Founder and CEO of Code Ocean. "This collaboration
truly enables large-scale, high-throughput collaboration both
internally at Lantern and also with their leading research partners
to accelerate the pace of oncology drug discovery."
"It's a given that science and
discovery needs to be continuous," said Panna Sharma, President & CEO of Lantern
Pharma. "We selected Code Ocean as our partner, as we
expect them to provide our scientists, researchers, data engineers
and collaborators with a best in class, reproducible and highly
secure platform environment while also improving the research
experience. Paired with our proprietary A.I., Code
Ocean's Compute Capsule's will allow us
and other researchers to take collaborative drug development
further and faster than before."
Lantern leverages advances in machine learning, genomics and
artificial intelligence to develop oncology therapies by using its
proprietary A.I. platform to discover biomarker signatures aimed at
uncovering mechanisms of action, suggesting potential combination
therapy approaches and identifying patients more likely to respond
to its pipeline of cancer therapeutics. Working with the Code Ocean
platform is expected to help increase team productivity and enhance
Lantern Pharma's ability to collaborate more rapidly
with its industry leading partners, including the National Cancer
Institute, Georgetown University,
Johns Hopkins & Fox Chase Cancer
Center, within a secure and agile research environment.
"Our multidisciplinary research team -- of
bioinformaticians, computational biologists, data scientists and
machine learning practitioners -- was up and running after a few
hours of onboarding, and able to fully use our existing languages,
tools and frameworks. By adopting Code Ocean as part of our tech
stack we have furthered our efforts to have a secure, replicable,
user-friendly and cloud-based computational environment that can be
leveraged both internally and with our global network of
collaborators," said Peter Carr,
Principal Platform Architect at Lantern Pharma.
The Code Ocean platform does not require the user to be an IT
expert to utilize the software properly. By integrating the
essential triplet– code, data and a computing environment– Code
Ocean is offering the most complete platform for computational
research that's on the market. Code
Ocean's unique Compute Capsules provide a
fundamentally easier and more efficient way for researchers to
create and safely share their work, which is essential to moving
science forward. This, combined with Lantern Pharma's
billions of data points, will allow researchers to have faster
access to more data than ever before, without being overwhelmed by
massive amounts of data management or the computational
structure.
About Code Ocean
Code Ocean is where great computational research is created,
organized and shared in one place. The Code Ocean platform provides
the best way for research teams to standardize research workflow,
and to track and reproduce all computations and discoveries. By
making it easier and more efficient for researchers to collaborate,
Code Ocean improves reproducibility, optimizes return on IT
investment, and saves time by automating repetitive functions. More
information is available at: www.codeocean.com and
Twitter @CodeOceanHQ.
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused
biopharmaceutical company leveraging its proprietary
RADR® A.I. platform and machine learning to
discover biomarker signatures that identify patients most likely to
respond to its pipeline of genomically targeted therapeutics.
Lantern is currently developing four drug candidates and an ADC
program across eight disclosed tumor targets, including two phase 2
programs. By targeting drugs to patients whose genomic profile
identifies them as having the highest probability of benefiting
from the drug, Lantern's approach represents the potential to
deliver best-in-class outcomes. More information is available
at: www.lanternpharma.com and Twitter @lanternpharma.
CONTACT
Code Ocean
David Butler
david@codeocean.com
Lantern Pharma
Nicholas Koulermos, 5W Public
Relations
lantern@5wpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/code-ocean-selected-by-lantern-pharma-to-power-ai-focused-computational-research-environment-for-oncology-drug-development-301407959.html
SOURCE Code Ocean